Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07450859 · ClinicalTrials.gov registry record · Phase 2

A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

A Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by BicycleTx Limited.

Recruiting
Registry status
Phase 2
Development phase
39
Enrollment target
1
Study location

NCT07450859 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC) that is actively recruiting participants, run by BicycleTx Limited. The registered enrollment target is 39 participants, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07450859, a Phase 2 study of Pancreatic Ductal Adenocarcinoma (PDAC), is actively recruiting participants, sponsored by BicycleTx Limited.

RECRUITING
Registry status
Phase 2
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 2 study for BT5528 in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, BT5528, is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive BT5528, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.

Conditions Studied

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • DRUG BT5528

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office - Philadelphia

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2026-03
Est. Completion 2029-05
Phase Phase 2

Sponsor

BicycleTx Limited

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07450859

The ClinicalTrials.gov registry entry for NCT07450859 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 294-participant average among 16 other Pancreatic Ductal Adenocarcinoma (PDAC) trials with a reported enrollment target (87% lower). The listed sponsor is BicycleTx Limited, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma (PDAC) appearing as the primary indexed condition, and to 1 intervention - of which BT5528 is the first listed.

NCT07450859 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07450859 about?

NCT07450859 is a clinical study titled "A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)". This is a Phase 2 study for BT5528 in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, BT5528, is designed to find a specific protein called EphA2. The main aims of the st...

What is the current status of trial NCT07450859?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2026-03. Estimated completion is 2029-05.

What conditions does trial NCT07450859 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma (PDAC).

What interventions are being tested in trial NCT07450859?

The interventions under investigation include: BT5528 (DRUG).

Who is sponsoring clinical trial NCT07450859?

This trial is sponsored by BicycleTx Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07450859 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Ductal Adenocarcinoma (PDAC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Ductal Adenocarcinoma (PDAC)

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.